Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akari Therapeutics PLC AKTX

Healthcare Biotechnology
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric... see more

Recent & Breaking News (NDAQ:AKTX)

Akari Announces Third Quarter 2018 Financial Results and Business Highlights

GlobeNewswire November 15, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane — New Research Emphasizes Economic Growth

GlobeNewswire October 25, 2018

Akari Therapeutics Announces New Clinical Data in Post-Transplant Thrombotic Microangiopathies. Data Supports Akari’s Ongoing Clinical Expansion into a Range of Orphan Autoinflammatory Diseases That Are Either Mediated by Complement C5 or Have Synchronous

GlobeNewswire September 30, 2018

Akari Announces Second Quarter 2018 Financial Results and Business Highlights

GlobeNewswire September 27, 2018

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC

GlobeNewswire September 27, 2018

Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 25, 2018

Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin’s bifunctional activity inhibiting both the Complement and Leukotriene Inflamma

GlobeNewswire September 12, 2018

Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire September 4, 2018

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Akari Therapeutics, plc -- AKTX

GlobeNewswire August 20, 2018

Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials

GlobeNewswire August 17, 2018

Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association

GlobeNewswire June 15, 2018

Market Trends Toward New Normal in Independent Bank, First Busey, American Public Education, The First Bancshares, Northfield, and Akari Therapeutics — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire May 25, 2018

Akari Therapeutics Announces Further Clinical Progress

GlobeNewswire October 11, 2017

Mid-Afternoon Market Update: Scholastic Falls After Q1 Results; Akari Therapeutics Shares Surge

Benzinga.com  September 21, 2017

Mid-Morning Market Update: Markets Fall; Initial Jobless Claims Drop to 259,000

Benzinga.com  September 21, 2017

Akari Therapeutics Announces Regulatory Progress Following FDA Meeting

GlobeNewswire September 21, 2017

Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 19, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  September 13, 2017

14 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  September 12, 2017

Akari Therapeutics Announces Appointment of David Horn Solomon as CEO

GlobeNewswire August 21, 2017